Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 27.24% is 186% above its 5-year average of -31.84%, near the high end of its 5-year range (-92.66%–27.24%).
As of the fiscal period ended Tuesday, June 30, 2026. 429.77% above its 12-month average of -8.26%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): 27.24%.
RETURN ON EQUITY (ROE)
27.24%
RETURN ON EQUITY (ROE) AVG TTM
-8.26%
RETURN ON EQUITY (ROE) AVG 3Y
-11.42%
RETURN ON EQUITY (ROE) AVG 5Y
-31.84%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+429.77%
CURRENT VS 3Y AVG
+338.59%
CURRENT VS 5Y AVG
+185.54%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.61%
median of 378 covered companies
CURRENT VS SECTOR MEDIAN
+183.53%
vs the sector median at left
Eton Pharmaceuticals, Inc.
Market Cap
$1.52B
Return on Equity (ROE)
27.24%
TTM Avg
-8.26%
3Y Avg
-11.42%
5Y Avg
-31.84%
Market Cap
$1.52B
Return on Equity (ROE)
-17.32%
TTM Avg
-19.51%
3Y Avg
-16.07%
5Y Avg
-12.58%
Market Cap
$1.51B
Return on Equity (ROE)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.57B
Return on Equity (ROE)
-7.08%
TTM Avg
-0.64%
3Y Avg
-1.30%
5Y Avg
-2.08%
Market Cap
$1.46B
Return on Equity (ROE)
1849.06%
TTM Avg
-120.25%
3Y Avg
-118.83%
5Y Avg
-82.76%
Market Cap
$1.45B
Return on Equity (ROE)
23.70%
TTM Avg
9.74%
3Y Avg
8.98%
5Y Avg
11.20%
Market Cap
$1.43B
Return on Equity (ROE)
N/A
TTM Avg
36.18%
3Y Avg
36.18%
5Y Avg
36.18%
Market Cap
$1.65B
Return on Equity (ROE)
N/A
TTM Avg
-1058.20%
3Y Avg
-465.87%
5Y Avg
-348.95%
Market Cap
$1.65B
Return on Equity (ROE)
17.72%
TTM Avg
5.08%
3Y Avg
0.03%
5Y Avg
-3.88%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Eton Pharmaceuticals, Inc. (ETON) | $1.52B | 27.24% | -8.26% | -11.42% | -31.84% |
| GH Research PLC (GHRS)vs › | $1.52B | -17.32% | -19.51% | -16.07% | -12.58% |
| Braveheart Bio, Inc. (BRVE)vs › | $1.51B | N/A | N/A | N/A | N/A |
| Certara, Inc. (CERT)vs › | $1.57B | -7.08% | -0.64% | -1.30% | -2.08% |
| AnaptysBio, Inc. (ANAB)vs › | $1.46B | 1849.06% | -120.25% | -118.83% | -82.76% |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.45B | 23.70% | 9.74% | 8.98% | 11.20% |
| Hemab Therapeutics Holdings, Inc. Common Stock (COAG)vs › | $1.43B | N/A | 36.18% | 36.18% | 36.18% |
| Alphatec Holdings, Inc. (ATEC)vs › | $1.65B | N/A | -1058.20% | -465.87% | -348.95% |
| ANI Pharmaceuticals, Inc. (ANIP)vs › | $1.65B | 17.72% | 5.08% | 0.03% | -3.88% |
| Alpha Tau Medical Ltd (DRTS)vs › | $1.34B | -210.13% | -52.98% | -43.11% | 1.89% |
ROE
27.2%
ROA
11.0%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | 27.24% |
| 2026-03-31 | -4.82% |
| 2025-12-31 | -17.59% |
| 2025-09-30 | -28.89% |
| 2025-06-30 | -17.23% |
| 2025-03-31 | -18.75% |
| 2024-12-31 | -15.65% |
| 2024-09-30 | -34.30% |
| 2024-06-30 | -49.67% |
| 2024-03-31 | 5.89% |
| 2023-12-31 | -6.05% |
| 2023-09-30 | 13.21% |
| 2023-06-30 | -1.40% |
| 2023-03-31 | -56.50% |
| 2022-12-31 | -68.98% |
| 2022-09-30 | -79.55% |
| 2022-06-30 | -90.19% |
| 2022-03-31 | -92.66% |
| 2021-12-31 | -11.09% |
| 2021-09-30 | -68.21% |
| 2021-06-30 | -53.49% |
| 2021-03-31 | -64.05% |
| 2020-12-31 | -178.57% |
| 2020-06-30 | -304.94% |
| 2020-03-31 | -187.94% |
| 2019-12-31 | -173.65% |
| 2019-09-30 | -156.74% |
| 2019-06-30 | -103.59% |
| 2019-03-31 | -89.03% |
| 2018-12-31 | -48.44% |
| 2018-09-30 | -340.99% |
| 2018-06-30 | -214.68% |
| 2018-03-31 | -150.42% |
